A “TP53/PPM1D” subgroup including patients with long history of cancer treatment and complex cytogenetics, a “MDS-like” subgroup with older patients, similar to standard high-risk MDS or secondary AML, and a “de novo/pan-AML” subgroup in which most patients have a balanced chromosomal translocation. Here, TP53 is linked to myelodysplastic syndrome.